Ultragenyx Pharmaceutical just hit a 52-week low and analysts have slashed and burned their price target expectations. This is after a late-stage trial did not live up to expectations.
Ultragenyx Pharmaceutical just hit a 52-week low and analysts have slashed and burned their price target expectations. This is after a late-stage trial did not live up to expectations.